Google News • 1/15/2026 – 1/16/2026
Ocugen has announced positive preliminary Phase 2 data from its OCU410 modifier gene therapy for geographic atrophy secondary to dry age-related macular degeneration. The company released 12-month data from the Phase 2 ArMaDa trial, indicating that the gene therapy continues to slow damage in geographic atrophy. This development positions Ocugen in competition with Apellis and Astellas.
Advertisement
Stories gain Lindy status through source reputation, network consensus, and time survival.


